Phase 2b/3 psoriatic arthritis clinical trial met the primary endpoint of ACR50 at 16 weeks versus placebo with high statistical significance. Robust responses were achieved for ACR70, PASI100,.
Solna, Sweden, December 20, 2023. Affibody’s licensee Rallybio Corporation today announced preliminary Phase 1 multiple ascending dose data for RLYB116, an innovative, long-acting, low volume.
Solna, Sweden, November 27, 2023. Affibody’s partner ACELYRIN, INC. today provided an update on its izokibep clinical development program, including the ongoing global Phase 2b/3 trial in psoriatic.
Notice of Annual General Meeting of Abliva AB (publ) privataaffarer.se - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from privataaffarer.se Daily Mail and Mail on Sunday newspapers.
Affibody and Chiesi Group partner to develop treatments pharmatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmatimes.com Daily Mail and Mail on Sunday newspapers.